Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Celcuity Inc.

CELC ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$65.57

▲ +6.51%

Market Cap $3.21B · Vol 446.53K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.21B

Mid Cap

Div Yield

N/A

EPS Growth

-35.88%

YoY

RSI (14)

40.01

Momentum

Beta

0.13

vs Market

52W High

$151.02

59.24% below

52W Low

$53.55

14.96% above

Volume

446.53K

Avg 389.61K

P/B

47.85

Price-to-book

ROE

N/A

Return on equity

Free Float

83.24%

Public shares

Shariah Compliance8 STANDARDS

✗ Celcuity Inc. (CELC) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CELC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+8.74%

-22.03%

-27.26%

-46.44%

YTD

-34.26%

-6.38%

+555.04%

+273.83%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-177,042,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-49.75% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	47.85
P/FCF	N/A
EPS Growth	-35.88%
Outstanding Shares	48.93M

Technical Indicators

50-Day SMA	$80.50
200-Day SMA	$101.82
RSI (14)	40.01
Beta	0.13
52-Week High	$151.02
52-Week Low	$53.55

Volume Today	446.53K
Avg Daily Volume (30D)	389.61K
Relative Volume	1.15x
Volatility (10D)	64.55
Volatility (30D)	56.45
Free Float	83.24%

Analyst Consensus

BUY

Current Price $65.57

Mean Target $154.50

52W Low$53.55 52W High$151.02

Current

Target

$53.55 $151.02

Current Analyst target

+135.63% upside potential · 11 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00HKBW054

ISINUS15102K1007

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.